Ergoteles’s Amicus Therapeutics FOLD Stock Holding History

Ergoteles’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-60,549	Closed	-$760K	–	342
2023 Q2	$760K	Sell	60,549 -261,595	-81%	-$3.1M	0.04%	535
2023 Q1	$3.57M	Buy	322,144 +112,678	+54%	+$1.39M	0.14%	123
2022 Q4	$2.56M	Buy	209,466 +183,197	+697%	+$2.06M	0.09%	220
2022 Q3	$274K	Buy	+26,269	New	+$293K	0.01%	1023
2021 Q3	–	Sell	-17,638	Closed	-$170K	–	1368
2021 Q2	$170K	Buy	+17,638	New	+$172K	﹤0.01%	1326
2020 Q4	–	Sell	-18,100	Closed	-$256K	–	755
2020 Q3	$256K	Buy	+18,100	New	+$264K	0.03%	392

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ergoteles's FOLD Position: Q3 2023 in Review

Ergoteles sold out of Amicus Therapeutics (FOLD) in Q3 2023, closing a stake of 60,549 shares — an estimated $760K sold.

Ergoteles first reported a position in FOLD in Q3 2020 and held it in 6 quarters. The position peaked at $3.57M in Q1 2023. 228 funds tracked by Wall St. Rank hold FOLD as of Q3 2023.

Ergoteles reported no remaining Amicus Therapeutics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 60,549 Amicus Therapeutics shares in Q3 2023, an estimated $760K.
Ergoteles first reported a position in Amicus Therapeutics in Q3 2020 and held it in 6 quarters.
Ergoteles's Amicus Therapeutics position peaked at $3.57M in Q1 2023.
228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.